Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 5/20 | 0.49 |
| ▸ | THRB | P10828 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.39 |
| ▸ | HSPH1 | Q92598 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5109300 | 0.90 | THRA (0.62) | THRATHRBLMNAALDH1A1FFAR4 | |
| SCHEMBL5107899 | 0.90 | THRA (0.51) | THRATHRBLMNAFFAR4FFAR1 | |
| SCHEMBL5107813 | 0.90 | THRB (0.46) | THRATHRBLMNAALDH1A1MAPT | |
| SCHEMBL5111277 | 0.89 | ALDH1A1 (0.46) | THRATHRBLMNAALDH1A1MRGPRX4 | |
| SCHEMBL4932268 | 0.88 | THRA (0.54) | THRATHRBFFAR4FFAR1MRGPRX4 | |
| SCHEMBL4932512 | 0.87 | THRA (0.53) | THRATHRBLMNAFFAR4FFAR1 | |
| SCHEMBL5109920 | 0.87 | THRA (0.48) | THRATHRBLMNAALDH1A1FFAR4 | |
| SCHEMBL4928689 | 0.87 | THRA (0.50) | THRATHRBFFAR4FFAR1MRGPRX4 | |
| SCHEMBL5118275 | 0.86 | THRA (0.45) | THRATHRBALDH1A1FFAR4FFAR1 | |
| SCHEMBL5103911 | 0.86 | THRA (0.47) | THRATHRBLMNAALDH1A1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004251-A1 | Novel Pharmaceutical Compositions Comprising Agonists of the Thyroid Receptor | KARO BIO AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004251-A1 | Novel Pharmaceutical Compositions Comprising Agonists of the Thyroid Receptor | TSHR, TRHR, THRA | THRA 3/4885THRB 4/4885LMNA 3643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.